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Mutagenesis directed to a speciﬁc glycosylation site has been widely used to examine biological
roles of individual glycans. However, occurrence of any post-translational modiﬁcation on such
deglycosylated mutants has not yet been well characterized. Here we performed mass spectrometric
analyses of the Fc fragment of an unglycosylated mutant of mouse immunoglobulin G2b, whose
conserved N-glycosylation site, i.e. Asn297, was substituted with alanine. We found that a major part
of this mutant is sulfated at Tyr296, which adjacently precedes the originally glycosylated site. Our
ﬁndings demonstrate that mutational deglycosylation can induce an unexpected post-translational
modiﬁcation in the protein.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Glycosylation is a diverse, enzyme-mediated process by which
oligosaccharide chains are covalently attached to either the side
chain of asparagine (N-linked) or serine/threonine (O-linked). The
carbohydrate moieties of proteins not only mediate molecular rec-
ognition events on cell surfaces [1–3] but also govern protein fold-
ing and quality control in cells [4–7], and consequently deﬁne the
active conformations of secreted proteins [8]. Understanding of the
biological functions of the carbohydrate moieties and their impact
on pharmaceutical properties of the carrier proteins is now crucial
in developing clinically safe and efﬁcacious glycoprotein as biosim-chemical Societies. Published by E
romatography; FT-ICR MS,
ometry; ESI-MS, electrospray
m bombardment-mass spec-
resonance
Science and Okazaki Institute
al Sciences, 5-1 Higashiyama,ilars and biobetters. This is because more than two-thirds of cur-
rently marketed therapeutic proteins, including monoclonal
antibodies, are glycosylated [9–13].
In order to examine the biological roles of the sugar chains, the
glycoproteins are often subjected to deglycosylation [14]. Pep-
tide:N-glycanase from Flavobacterium meningosepticum is used for
the removal of N-glycans [15–17]. Also, tunicamycin, a glycosyla-
tion inhibitor, has been widely used for depletion of N-linked oligo-
saccharides [18–20]. These treatments result in non-selective
elimination of the N-glycans and therefore provide little informa-
tion of individual glycans. By contrast, elimination of speciﬁc gly-
cans can be achieved by employing site-directed mutagenesis
technology, typically substituting the glycosylated asparagine res-
idues with other amino acids [9–11].
The mutational deglycosylation is used not only for elucidating
functional relevance of individual glycans but also for simplifying
the procedures in structural analyses of glycoproteins, enabling a
wide range of options for therapeutic antibody biomanufacture,
and reducing antigenicities of glycans in clinical applications
[21–23]. This technique has been widely used with the assumption
that the mutation induces no impact on the covalent structure oflsevier B.V. All rights reserved.
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from the amino acid substitution. To date, however, this assump-
tion has not been extensively tested. In the present work, hence,
we performed a detailed mass spectrometric analysis of a muta-
tionally unglycosylated mouse IgG2b by replacement of N-glycos-
ylated asparagine, Asn297, with alanine (N297A) [24]. The Fc
fragment of this IgG2b mutant was structurally characterized by
combined use of various mass spectrometric techniques. During
the course of this study, we found that the aglycosylated IgG2b
mutant is actually sulfated at the tyrosine residue adjacently pre-
ceding the originally glycosylated site. The possible signiﬁcance
of this ﬁnding will be brieﬂy discussed.
2. Results
2.1. Electrospray ionization-mass spectrometry (ESI-MS) analysis of
N297A-Fc
For the mass spectrometric analyses, the Fc fragment with a
homogeneous N-terminal was cleaved from the N297A mutant of
mouse IgG2b by lysylendopeptidase digestion [25]. As expected
from the previous results [26], this Fc mutant contained no N-gly-
cans, which was conﬁrmed by the high-performance liquid chro-
matography (HPLC)-based glycosylation proﬁling (data not
shown). The Fc fragment was reduced and alkylated and then sub-
jected to ESI-MS analysis. Molecular mass of the polypeptide chain
of reduced and alkylated Fc mutant was calculated as 24512.9 Da
on the basis of the amino acid sequence. Unexpectedly, one major
and one minor ion peaks (24 514.8 and 24 594.7 Da, respectively)
were observed in the spectra with mass differences of 80 without
any modiﬁcation (Fig. 1). This strongly suggests that a major part
(ca. 80%) of the N297A-Fc fragment is modiﬁed with one sulfate
or phosphate adduct.
2.2. Peptide mapping of N297A and wild-type Fc
To identify the modiﬁcation in N297A-Fc, we performed peptide
mapping of the N297A-Fc fragment in comparison with a typically
glycosylated Fc of mouse IgG2b (Fig. 2A). The V8 protease digestion
products of these Fc fragments were loaded onto an ODS column.
Subsequently, the peptides with different elution times between
the HPLC proﬁles (peak A from the glycosylated Fc and peaks B24000 24100 24200 24300 24400 24
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Fig. 1. Transformed nano ESI-MS spectrum of the reduced and aand C from the N297A-Fc) were isolated and subjected to MAL-
DI-TOF-MS analyses. The MS data suggested that all the three
peaks correspond to the peptide spanning from Asp295 to
Glu318 but with distinct modiﬁcations (Fig. 2B). The peak A frac-
tion contained the two glycopeptides: one carries (Fuc)(Hex)3(Hex-
NAc)4 and the other (Fuc)(Hex)4(HexNAc)4, which is consistent
with the typical N-glycosylation proﬁles of mouse IgG2b-Fc
[27,28]. On the other hand, peaks B and C corresponded to the
N297A peptides with and without modiﬁcation with the 80-Da ad-
duct, respectively (Fig. 2B), showing that the modiﬁcation occurs in
this segment. In order to identify the 80-Da adduct discriminating
between sulfate (80.964 Da) and phosphate (80.974 Da), we per-
formed fourier transform ion cyclotron resonance mass spectrom-
etry (FT-ICR MS) measurement of the peptide corresponding to
peak b (Fig. 3). The high resolution/accuracy mass spectrometric
data eventually allowed us to conclude that the peptide is
monosulfated.
2.3. Fast atom bombardment-mass spectrometry/mass spectrometry
(FAB-MS/MS) analyses of the peptide (D295-R301)
In order to identify the sulfated amino acid residue, the peptide
(Asp295-Glu318) was split into two tryptic peptides (Asp295-
Arg301 and Val302-Glu318), which were isolated by using an
ODS column and subjected to MS analyses. The MALDI-TOF-MS
data showed that the Asp295-Arg301peptide contains the 80-Da
adduct, whilst the Val302-Glu318 peptide has no modiﬁcation
(data not shown). We further conducted the FAB-MS/MS analysis
of the sulfated peptide (Fig. 4). Inspection of the fragment pattern
revealed that Tyr296 is the sulfated amino acid residue. We also
observed the liberated SO3 ions (m/z 80) in the FAB-MS/MS spec-
trum, conﬁrming the existence of sulfate group.
3. Discussion
Our detailed mass spectrometric analysis revealed that the
mutational deglycosylation at position 297 causes sulfation of
Tyr296 in mouse IgG2b. By using [35S] sulfate labeling method,
Beauerelr and Huttner reported that tunicamycin treatments of
antibody-producing hybridoma cells induce tyrosine O-sulfation
of secreted mouse IgG2a [29]. Tunicamycin is now widely used
as an inducer of endoplasmic reticulum stress because this uridine500 24600 24700 24800 24900 25000
ass (Da)
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24594.7
lkylated Fc fragment of the N297A mutant of mouse IgG2b.
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Fig. 2. Peptide mapping of the IgG2b-Fc fragments. (a) Elution proﬁles on an ODS column of the glycosylated (upper) and aglycosylated (lower) Fc fragments. (b) MALDI-TOF-
MS spectra of the peptides corresponding to the Asp295-Glu318 segment of the glycosylated (upper) and aglycosylated IgG2b (lower).
3476 K. Masuda et al. / FEBS Letters 584 (2010) 3474–3479analogue non-selectively blocks the biosynthesis of N-linked
glycans by disrupting the assembly of their common pentasaccha-
ride core. The present data clearly demonstrate that sulfation oc-
curs at the speciﬁc tyrosine residue of IgG2b as a result of the
removal of the speciﬁc glycan of this glycoprotein.
Tyrosine sulfation is catalyzed by membrane-bound tyrosylpro-
tein sulfotransferases (TPSTs) in the trans-Golgi network [30]. Until
now, two different enzymes, i.e. TPST1 and TPST2, have been con-
servatively identiﬁed in mammals [31–34]. In vitro sulfation stud-ies using model peptides demonstrate a considerable degree of
overlap in substrate speciﬁcities between these two enzymes
[35]. It has been reported that tyrosine sulfation preferentially oc-
curs in the vicinity of acidic residues [36]. Indeed, Tyr296 is di-
rectly preceded by an aspartate residue (Asp295) in mouse IgG2b
as well as IgG2a.
In the trans-Golgi network, the tertiary and quaternary struc-
tures of proteins are supposed to have been completed already.
Among all tyrosine residues in the Fc portion of mouse IgG2b,
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Fig. 3. FT-ICR mass spectrometric analysis of sulfopeptide Asp295-Glu318 derived from N297A.
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Fig. 4. High-energy FAB-MS/MS spectrum of the [M–H] ion of the sulfopeptide Asp295-Arg301 derived from N297A.
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accessibility of the side chain [37], which, however, may not be
sufﬁcient for the approach of TPSTs, judging from the fact that this
tyrosine is not sulfated in the glycosylated IgG2b-Fc. The X-ray
crystallographic data as well as nuclear magnetic resonance data
of mouse IgG2b show that the N-glycan partially masks Tyr296
side chain [37,38]. Hence, it is quite likely that the side chain of this
tyrosine becomes so exposed upon deglycosylation to be accessi-ble to TPST(s). The tyrosine sulfation may serve as a signal
for the secretion in the absence of the N-glycans [29] or increase
the solubility of IgG by masking the solvent-exposed tyrosine
residue.
In summary, our ﬁndings demonstrate that mutational deglyco-
sylation can induce an unexpected post-translational modiﬁcation
in the protein, which may inﬂuence its functional, immunoreac-
tive, and/or biopharmaceutical properties.
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4.1. Materials
Trypsin was purchased from Sigma Chemical Co. Staphylococcus
aureus V8 protease and lysylendopeptidase were from Wako Pure
Chemical Industries, Ltd.
4.2. Protein expression and puriﬁcation
In this study, the N297A mutant of mouse anti-nitroiodophe-
nacetyl hapten (NIP) IgG2b [24] and mouse anti-dansyl IgG2b
27–35.8 [39] were used as sources of the aglycosylated and glycos-
ylated Fc fragments, respectively. The mouse hybridoma cells pro-
ducing these IgG2bs were adapted to a modiﬁed Nissui NYSF 404
serum-free medium [40], where dihydroxyethylglycine had been
replaced by 15 mM HEPES. The cells were grown in the medium
in tissue culture ﬂasks (Corning) lying still at 37 C in a humidiﬁed
atmosphere of 5% CO2/95% air [41,42]. IgG2bs were puriﬁed as de-
scribed previously [41,42].
4.3. Fragmentation of IgG2b by lysylendopeptidase
The Fc fragment of the IgG2b-N297A mutant was prepared by
lysylendpeptidase digestion at 37 C for 1 h in 50 mM Tris–HCl buf-
fer, pH 8.5 as described previously [25]. The HPLC-based glycosyl-
ation proﬁling technique [43,44] was employed to conﬁrm the
aglycosylation of the Fc fragment. Protocols for mild reduction
and alkylation of Fc were described as in the previous paper [28].
4.4. Mass spectrometry
4.4.1. MALDI-TOF-MS
Samples were spotted on a sample plate and mixed with the
matrix solutions, saturated sinapic acid (Fluka) or a-cyano-4-
hydroxycinnamic acid (Fluka) in 50% acetonitrile/H2O containing
0.1% (v/v) triﬂuoroacetic acid. Mass spectra were obtained by MAL-
DI-TOF-MS using a Shimadzu Kompact MALDI IV mass
spectrometer.
4.4.2. FAB-MS/MS
HPLC fraction was dissolved in H2O and analyzed using a 1:1 (v/
v) mixture of glycerol as a matrix. The FAB-MS/MS analyses were
performed using a JEOL JMS-HX110/HX110 mass spectrometer
equipped with a high ﬁeld magnet. The mass spectrometer was
operated in the negative-ion mode. The spectra were recorded
using an accelerating voltage of 10 kV. Xenon was the neutral
particle source. The mass range (m/z 20–3500) was calibrated with
CsI cluster ions.
4.4.3. FT-ICR MS
High-resolution mass measurements for exact mass determina-
tion of the sulfopeptides were carried out using a Bruker APEX III
Fourier transform mass spectrometer equipped with a 7 tesla
superconducting magnet and the external electrospray ion source
(apollo source). The spectra were externally calibrated with a cap-
illary skimmer dissociation spectrum of LHRH (lutheinizing hor-
mone releasing hormone) free acid. The samples were introduced
into the electrospray ion source using a 250 lL syringe with a syr-
inge pump ﬂow 2 lL/min.
4.4.4. ESI-MS
Nano ESI-MS was acquired using a Micromass Q-TOF mass
spectrometer and MassLynx data acquisition. This instrument is a
hybrid quadrupole orthogonal acceleration time-of-ﬂight massspectrometer, with a Z-spray nanoﬂow electrospray ion source.
The mass spectrometer was operated in the positive-ion mode.
Puriﬁed sample was extensively dialyzed against water, lyophi-
lized and then dissolved at a protein concentration of 10 lM in a
solution containing equal amounts of acetonitrile and 0.2% formic
acid. Two microliters of the sample solution was loaded into a
nanoﬂow tip. A ﬂow rate of about 50 nl/min into the analyzer
was produced as a result of a potential of 1.5 kV applied to the
nanoﬂow tip in the ion source. The cone voltage was set to 50 V.
Twenty spectra were averaged, baseline subtracted, smoothed,
centroided and deconvoluted.
4.5. Peptide mapping
Peptide mapping of glycosylated and aglycosylated Fc frag-
ments were performed as described previously [45]. Brieﬂy, Fc
fragments were reduced and alkylated in the presence of 6 M
guanidinium chloride, and the reaction mixture was dialyzed
against 50 mM NH4HCO3 buffer pH 7.9, and then lyophilized. The
lyophilized sample was re-dissolved in 50 mM NH4HCO3 buffer
pH 7.9, and then incubated in the presence of V8 protease at an en-
zyme/substrate molar ratio of 1:30 at 37 C for 12 h. The reaction
mixture was loaded onto a YMC ODS A-312 reverse-phase column
(Yamamura Chemical Laboratories). Fractionated peptides were
lyophilized and then subjected to a MALDI-TOF-MS analysis on a
Shimadzu Kompact MALDI IV mass spectrometer.
The peptide corresponding to the Asp295 to Glu318 segment of
N297A was further digested with trypsin (2 lg/ml) in 50 mM
NH4HCO3, pH 7.9 at a peptide concentration of 10 nmol/ml at
37 C for 6 h. The reaction mixture was lyophilized, dissolved in
0.1% (v/v) TFA and applied onto a YMC ODS A-312 reverse-phase
column to isolate the peptide spanning from Asp295 to Arg301.
The HPLC conditions were the same as those employed in the pep-
tide mapping experiments described above.Acknowledgements
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